Barclays raised the firm’s price target on CME Group (CME) to $257 from $231 and keeps an Equal Weight rating on the shares. The macro backdrop looks constructive going into 2025 for the brokers, asset managers and exchanges, the analyst tells investors in a research note. The firm is increasingly constructive on the alternative asset managers, where an “unleash” of transacting has been growing and looks set to happen, and brokers, where it sees healthy earnings growth opportunities.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CME:
- Mali Issues Arrest Warrant for Barrick Gold (GOLD) CEO amid Rising Tensions
- CME Group Announces Share Repurchase and Dividend Plan
- CME Group announces $2.1B annual variable dividend, $3B share repurchase plan
- CME Group reports November ADV of 30.2M contracts
- CME Group and LPGA announce extension of the CME Group Tour Championship
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
